Mandate

Vinge advises EQT in connection with sale of care giant Aleris

July 02, 2010

EQT III has entered into an agreement to sell the Aleris healthcare group to Investor AB. The transaction value is SEK 4.4 billion with a supplementary purchase price of up to SEK 100 million. The transaction is subject to approval by the relevant competition authorities.

The Vinge team advising EQT consisted of Tuula Tallavaara, David Andersson, Johan Mattsson and Ulrich Ziche. Peter Alstergren provided competition law advice and Carl Gustav De Geer was the responsible partner.

Aleris has approximately 5000 employees and has operations in Sweden, Norway and Denmark. Aleris’ turnover in 2009 was approximately SEK 4 billion.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026